Bank Of New York Mellon Corp Passage Bio, Inc. Transaction History

Bank Of New York Mellon Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$1.06 - $1.48 $14,465 - $20,197	13,647 New	13,647 $18,000
Q3 2022 Nov 14, 2022	SELL	$1.22 - $2.48 $6,163 - $12,528	-5,052 Reduced 27.02%	13,647 $17,000
Q2 2022 Aug 15, 2022	SELL	$1.63 - $3.46 $178,807 - $379,555	-109,698 Reduced 85.44%	18,699 $44,000
Q1 2022 May 11, 2022	SELL	$2.66 - $6.49 $1,859 - $4,536	-699 Reduced 0.54%	128,397 $398,000
Q4 2021 Feb 11, 2022	SELL	$6.24 - $10.2 $1.15 Million - $1.88 Million	-183,912 Reduced 58.76%	129,096 $820,000
Q3 2021 Nov 12, 2021	BUY	$9.73 - $15.52 $180,296 - $287,585	18,530 Added 6.29%	313,008 $3.12 Million
Q2 2021 Aug 11, 2021	BUY	$12.44 - $19.45 $167,268 - $261,524	13,446 Added 4.78%	294,478 $3.9 Million
Q1 2021 May 13, 2021	BUY	$16.24 - $29.83 $1.51 Million - $2.78 Million	93,137 Added 49.57%	281,032 $4.91 Million
Q4 2020 Feb 09, 2021	BUY	$14.28 - $29.73 $355,229 - $739,563	24,876 Added 15.26%	187,895 $4.8 Million
Q3 2020 Nov 12, 2020	SELL	$12.39 - $26.15 $114,012 - $240,632	-9,202 Reduced 5.34%	163,019 $2.14 Million
Q2 2020 Aug 12, 2020	BUY	$14.59 - $36.07 $2.51 Million - $6.21 Million	172,221 New	172,221 $4.71 Million

38.7M

7.7K

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $31.6M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.